Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 82Carcinoma, Non-Small-Cell Lung 72Carcinoma, Renal Cell 42Neoplasm Metastasis 31Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Lung Neoplasms 25Colorectal Neoplasms 23Carcinoma, Hepatocellular 20Hodgkin Disease 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 14Carcinoma, Transitional Cell 13Head and Neck Neoplasms 12Urinary Bladder Neoplasms 11Pancreatic Neoplasms 11Ovarian Neoplasms 11Multiple Myeloma 11Advanced Cancer 11Triple Negative Breast Neoplasms 10Lymphoma 10Glioblastoma 10Kidney Neoplasms 9Breast Neoplasms 9Recurrence 8Lymphoma, Non-Hodgkin 8Leukemia, Myeloid, Acute 8Glioma 8Stomach Neoplasms 7Myelodysplastic Syndromes 7

Interventions

pembrolizumab 2ribociclib 1napabucasin 1epacadostat 1amrubicin 1Sunitinib 1Plicamycin 1Paclitaxel 1Nivolumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thymus Neoplasms × Nivolumab × Clear all
NCT03447470 2025-01-29

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Redx Pharma Ltd

Phase 1 Completed
46 enrolled 29 charts
Gastrointestinal

Biliary Tract Neoplasms, Neoplasms, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡